{
  "company": {
    "name": "Avammune Therapeutics",
    "website": "https://avammune.com/",
    "record": "https://startuphistory.org/c/avammune.com"
  },
  "status": null,
  "history_since": "2019-07-04T04:16:57.000Z",
  "baseline": {
    "snapshot_id": "6e9facfdfe736834cdcc399004711f89cf1e15bb8ebda5c5ee7b9cffc54cd079",
    "observed_at": "2019-07-04T04:16:57.000Z",
    "headline": null,
    "description": "Avammune Therapeutics",
    "evidence": "https://web.archive.org/web/20190704041657/http://www.avammune.com:80/",
    "evidence_kind": "internet_archive",
    "facts": null,
    "basis": "first_observation",
    "is_change": false
  },
  "live_captures": 1,
  "last_checked": "2026-11-05T11:42:47.238Z",
  "live_status": null,
  "messaging": [
    {
      "quote_observed_at": "2025-06-13T22:43:13.000Z",
      "variants": [
        {
          "headline": "INNATE IMMUNITY",
          "subhead": "Avammune is developing highly potent non-nucleotidic small molecules inhibitors of Ectonucleotide Pyrophosphatase I (ENPP1) and more",
          "observed_at": "2021-11-26T08:53:12.000Z",
          "evidence": "https://web.archive.org/web/20211126085312/http://avammune.com/",
          "evidence_kind": "internet_archive"
        },
        {
          "headline": "INNATE IMMUNITY",
          "subhead": "Avammune is developing highly potent non-nucleotidic small molecules inhibitors of Ectonucleotide Pyrophosphatase I (ENPP1) and more",
          "observed_at": "2023-01-14T18:27:13.000Z",
          "evidence": "https://web.archive.org/web/20230114182713/https://www.avammune.com/",
          "evidence_kind": "internet_archive"
        },
        {
          "headline": "INNATE IMMUNITY",
          "subhead": "Avammune is developing highly potent non-nucleotidic small molecules inhibitors of Ectonucleotide Pyrophosphatase I (ENPP1) and more",
          "observed_at": "2024-07-24T21:52:09.000Z",
          "evidence": "https://web.archive.org/web/20240724215209/https://www.avammune.com/",
          "evidence_kind": "internet_archive"
        },
        {
          "headline": "INNATE IMMUNITY",
          "subhead": "Avammune is developing highly potent non-nucleotidic small molecules inhibitors of Ectonucleotide Pyrophosphatase I (ENPP1) and more",
          "observed_at": "2025-06-13T22:43:13.000Z",
          "evidence": "https://web.archive.org/web/20250613224313/http://www.avammune.com/",
          "evidence_kind": "internet_archive"
        }
      ],
      "headline": "INNATE IMMUNITY",
      "subhead": "Avammune is developing highly potent non-nucleotidic small molecules inhibitors of Ectonucleotide Pyrophosphatase I (ENPP1) and more",
      "from": "2021-11-26T08:53:12.000Z",
      "to": "2025-06-13T22:43:13.000Z",
      "captures": 4,
      "evidence": "https://web.archive.org/web/20250613224313/http://www.avammune.com/",
      "evidence_kind": "internet_archive",
      "seen": {
        "between": {
          "from": "2021-11-26T08:53:12.000Z",
          "to": "2025-06-13T22:43:13.000Z"
        }
      },
      "current": false
    },
    {
      "quote_observed_at": "2026-11-05T11:42:47.238Z",
      "variants": [
        {
          "headline": "Multi-Modal Cancer Therapies",
          "subhead": "Avammune develops first-in-class and best-in-class small-molecule therapeutics across foundational therapeutic modalities in oncology, enabling early POC-driven partnerships for the development of pio",
          "observed_at": "2026-02-04T20:10:59.000Z",
          "evidence": "https://web.archive.org/web/20260204201059/https://www.avammune.com/",
          "evidence_kind": "internet_archive"
        },
        {
          "headline": "Multi-Modal Cancer Therapies",
          "subhead": "Avammune develops first-in-class and best-in-class small-molecule therapeutics across foundational therapeutic modalities in oncology, enabling early POC-driven partnerships for the development of pio",
          "observed_at": "2026-11-05T11:42:47.238Z",
          "evidence": "https://www.avammune.com/",
          "evidence_kind": "live_capture"
        }
      ],
      "headline": "Multi-Modal Cancer Therapies",
      "subhead": "Avammune develops first-in-class and best-in-class small-molecule therapeutics across foundational therapeutic modalities in oncology, enabling early POC-driven partnerships for the development of pio",
      "from": "2026-02-04T20:10:59.000Z",
      "to": "2026-11-05T11:42:47.238Z",
      "captures": 2,
      "evidence": "https://www.avammune.com/",
      "evidence_kind": "live_capture",
      "seen": {
        "between": {
          "from": "2026-02-04T20:10:59.000Z",
          "to": "2026-11-05T11:42:47.238Z"
        }
      },
      "current": true
    }
  ],
  "changes": [
    {
      "n": 1,
      "id": "page-6afffe3e8e4eeab62284369f462365b079a38a0513b09157eb30a260ecaeddd7:3a225dd340f69c9744ce1a8c3b060101a4537eab1836072b55f3956be7aae530:funding:60da0d3109242220",
      "before_evidence": "https://web.archive.org/web/20230114182713/https://www.avammune.com/",
      "before_evidence_kind": "internet_archive",
      "kind": "funding",
      "label": "Funding",
      "summary": "Announced on its homepage: “Avammune Therapeutics (a spin-off from Aten Porus Lifesciences) secures a round of financing for completion of IND enabling studies for t…”.",
      "between": {
        "from": "2023-01-14T18:27:13.000Z",
        "to": "2024-07-24T21:52:09.000Z"
      },
      "evidence": "https://web.archive.org/web/20240724215209/https://www.avammune.com/",
      "evidence_kind": "internet_archive",
      "basis": "page_facts",
      "topic": "https://startuphistory.org/t/announced-funding"
    },
    {
      "n": 2,
      "id": "classifier-765d597410b6610cca5e12c6bcb1822de216d7d7f285c20771d22481814da9ea:b64ee3735951c626ff95f68aa21bcedf2438a6e94878f57fcbf17177f4eb796a:repositioning",
      "before_evidence": "https://web.archive.org/web/20250613224313/http://www.avammune.com/",
      "before_evidence_kind": "internet_archive",
      "kind": "repositioning",
      "label": "Messaging",
      "summary": "Changed its homepage headline from “INNATE IMMUNITY” to “Multi-Modal Cancer Therapies”.",
      "between": {
        "from": "2025-06-13T22:43:13.000Z",
        "to": "2026-02-04T20:10:59.000Z"
      },
      "evidence": "https://web.archive.org/web/20260204201059/https://www.avammune.com/",
      "evidence_kind": "internet_archive",
      "basis": "classifier",
      "topic": "https://startuphistory.org/t/repositioned"
    }
  ],
  "update": null,
  "method": {
    "version": "messaging-v1",
    "description": "https://startuphistory.org/method"
  },
  "license": "CC-BY-4.0",
  "cite": "StartupHistory, “Avammune Therapeutics” company record, https://startuphistory.org/c/avammune.com"
}